The development of new radionuclides and radiopharmaceuticals is pivotal to the future of nuclear medicine. Alpha-emitting radionuclides, such as actinium-225 and thorium-227, are gaining substantial attention due to their unique properties. These radionuclides emit high energy and short-range alpha particles, making them ideal for targeted cancer therapy [1,2]. These novel radionuclides deliver a potent radiation dose to a specific area, effectively destroying cancer cells while sparing surrounding healthy tissues. There is a promising shift towards personalized medicine in the context of radiopharmaceuticals. Advances in radiopharmaceuticals, drugs that contain radionuclides, are expected to usher in an era of precision medicine. Each patient's treatment plan will be tailored based on their unique genetic makeup and disease characteristics [1,2]. For instance, radiopharmaceuticals can be designed to target specific biomarkers or genetic mutations within a patient's tumor, allowing for highly personalized treatment regimens.

In addition to cancer therapy, these radiopharmaceuticals have applications in various fields, such as cardiology and neurology. For example, cardiology uses them for myocardial perfusion imaging, providing crucial insights into the blood flow to the heart muscle. In neurology, radiopharmaceuticals are used for brain imaging, enabling the diagnosis and evaluation of conditions like Alzheimer's disease.